skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Gain Clarity of Sight into What Comes Next with Citeline
According to Informa’s Pharmaprojects, less than 3% of all rare congenital and genetic diseases have an approved therapy. Opportunities abound ­if you know the risks.

Make better strategic and planning decisions with Intelligence services that give you a clear line of sight, helping you maximize clinical and commercial opportunities, navigate uncertainties, and ensure more successful outcomes. 

 

 

Future Treatment Approaches for Rare Congenital and Genetic Diseases

Gleaned from trusted data on the latest global developments, diseases, and treatment modalities, our experts share what you need to know:

  • Key indications for the top drugs in active development and which companies are leading the way
  • Drugs coming up for approvals – which will likely be given the green light by the US FDA?
  • Commercial deals, acquisitions and the specialist players who are prime targets
 
Rare Disease Whitepaper
Download Whitepaper

Attaining Insights on the Rare Disease Drug Development Landscape

Find out how we help our customers succeed with bespoke intelligence into the current and future commercial, regulatory and R&D pharma space.

  • Top 20 companies with Orphan Drug status
  • Orphan drug search functionality in Pharmaprojects
  • Top 5 rare diseases with “fallen angels”
  • How to identify “fallen angel” drugs for rare diseases
  • Top 6 reasons for “fallen angel” drug status
 
Rare Disease Case Study
Download now
Learn what Citeline can do for you:

Request a call from a member of the Citeline team to learn about our intelligence solutions including: 

  • Trialtrove - Clinical trial intelligence
  • Sitetrove - Clinical trial site & investigator identification
  • Pharmaprojects - Drug development intelligence
  • Citeline Engage - Gather feedback from experts, ignite awareness of your clinical studies, and recruit experienced investigators

 

Learn how Citeline solutions have helped companies succeed by leveraging our expertise and gold-standard intelligence. Register for a demo

 

 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free   : +1 888 670 8900  
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (20) 805 20700

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now